La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Thorne HealthTech Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Paul Jacobson

Amministratore delegato

US$4.1m

Compenso totale

Percentuale dello stipendio del CEO	13.0%
Mandato del CEO	13.8yrs
Proprietà del CEO	n/a
Durata media del management	9.8yrs
Durata media del Consiglio di amministrazione	8.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 12

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Aug 09

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Jun 05

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Mar 23

Thorne HealthTech: Good Potential At A Low Price

Jan 11

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Paul Jacobson rispetto agli utili di Thorne HealthTech?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	US$20m
Mar 31 2023	n/a	n/a	US$10m
Dec 31 2022	US$4m	US$530k	US$16m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	US$13m	US$530k	US$4m
Sep 30 2021	n/a	n/a	-US$822k
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$759k	US$530k	-US$3m

Compensazione vs Mercato: La retribuzione totale di Paul ($USD 4.09M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: La retribuzione di Paul è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Paul Jacobson (68 yo)

13.8yrs

Mandato

US$4,088,000

Compensazione

Mr. Paul F. Jacobson Co-Founded Thorne HealthTech, Inc. in 2010 and has been its Chief Executive Officer and Director since 2010. He is Chairman of Thorne HealthTech, Inc. He was Interim Principal Financi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Jacobson	Co-Founder	13.8yrs	US$4.09m	Nessun dato
William McCamy	President	no data	US$1.35m	Nessun dato
Saloni Varma	CFO & Director	less than a year	US$463.20k	0.032% $ 173.4k
Thomas McKenna	COO & Director	13.8yrs	US$2.89m	Nessun dato
Scott Hurth	Chief Technology Officer	9.8yrs	Nessun dato	Nessun dato
Nathan Price	Chief Scientific Officer & CEO of Onegevity	no data	Nessun dato	Nessun dato
Thomas Wilson	VP & Head of Investor Relations	no data	Nessun dato	Nessun dato
Kim Pearson	General Counsel	28.8yrs	Nessun dato	Nessun dato
Michelle Crow	Chief Marketing Officer	5.9yrs	Nessun dato	Nessun dato
Rob Monteleone	Senior VP of Professional Sales	no data	Nessun dato	Nessun dato
Bodi Zhang	Chief Strategy Officer	no data	Nessun dato	Nessun dato
Stephen Phipps	Chief Innovation Officer	2.8yrs	Nessun dato	Nessun dato

9.8yrs

Durata media

45.5yo

Età media

Gestione esperta: Il team dirigenziale di THRN è esperto e expertise (durata media dell'incarico 9.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Jacobson	Co-Founder	13.8yrs	US$4.09m	Nessun dato
Saloni Varma	CFO & Director	2.1yrs	US$463.20k	0.032% $ 173.4k
Thomas McKenna	COO & Director	13.8yrs	US$2.89m	Nessun dato
Riccardo Braglia	Independent Director	11.8yrs	Nessun dato	0% $ 0
Sarah Kauss	Independent Director	2.1yrs	US$469.45k	0.021% $ 114.6k
Toshitaka Inuzuka	Independent Director	5yrs	Nessun dato	0% $ 0

8.4yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di THRN sono considerati esperti (durata media dell'incarico 8.4 anni).

Thorne HealthTech Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Thorne HealthTech, Inc. Announces Executive Changes

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Recent updates

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Price target increased by 11% to US$8.36

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Investor sentiment improves as stock rises 27%

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Thorne Healthtech, Inc. Provides Earnings Guidance for 2023

Thorne HealthTech, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 8.7% to US$7.50

Thorne HealthTech Reportedly Working with Bank to Explore Sale

Investor sentiment improves as stock rises 17%

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

First quarter 2023 earnings: EPS misses analyst expectations

Thorne HealthTech, Inc. Reaffirms Financial Guidance for the Full-Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. (NasdaqGS:THRN) acquired PreCon Health, Inc. from Eigenlyfe LLC for $5 million.

Investor sentiment improves as stock rises 15%

Thorne HealthTech, Inc. Announces Executive Changes

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

Investor sentiment improved over the past week

Thorne Healthtech's OneDraw Device Used in Department of Defense's Cancer Moonshot 2.0 Project, Prometheus, as Part of President Biden Initiative

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Net Sales Guidance for the Full Year 2022

Thorne HealthTech, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Thorne HealthTech Grows But Faces Macro Headwinds

Thorne Healthtech's OneDraw(TM) Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Sales Guidance for the Full-Year 2022

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Investor sentiment improved over the past week

Thorne HealthTech, Inc. Achieves Self-Affirmed GRAS Status for Nicotinamide Riboside Malate Product

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from Russell 2500 Value Index

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Thorne HealthTech, Inc. Relaunches Gut Health Test

Thorne HealthTech, Inc. Relaunches Gut Health Test

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Consensus forecasts updated

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Full year 2021 earnings: EPS misses analyst expectations

Thorne HealthTech: Good Potential At A Low Price

Forecast breakeven date pushed back to 2022

Forecast to breakeven in 2021

Thorne HealthTech, Inc. has completed an IPO in the amount of $70 million.

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media